Pharma

View All

Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands

Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis (IPF) market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since the FDA green-lighted the medications in October 2014. And this week, both drugmak...

Find More


Sjogren’s syndrome- Autoimmune Attack on Salivary and Tear Glands

Sjögren's syndrome was named on Henrik Sjögren who described this indication in 1933, and is a chronic autoimmune disease in which body’s own immune system and white blood cells attack moisture producing glands such as tear and salivary glands, leading to dry mouth and eyes. There are certain other symptoms involved...

Find More

Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika

Aurobindo Pharma Q2 net profit up 33.53% to Rs. 606 cr Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust formulation sales. The company had posted a net profit after tax, minority interest and share of profit of jo...

Find More

Neprilysin Inhibitor for Cardiovascular Diseases

According to National Society of Health, approximately 26 million patients are suffering from heart failure worldwide, with the increased economic burden of USD 30.7 billion each year. The advent of a novel class of drugs, i.e., the angiotensin receptor-neprilysin inhibitor, gives hope to the patients. Neprilysin is...

Find More

Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV

Boston Biomedical starts phase III study of Napabucasin Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced dosing of the first patient in CanStem303C, a new global phase III study investigating napabucasin in combination with standard of...

Find More

Delveinsight
DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic ...

Find More

Delveinsight
Metastatic Prostate Cancer-Pipeline Insights, 2014

The “ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report by DelveInsight provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides in...

Find More

Delveinsight
DelveInsight- Business Consultant and Knowledge Partner

We DELVEINSIGHT are Business Consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. Our company can provide valuable insight across all Pharmaceutical industries which include Drug Manufacturing to API Manufacturers&nb...

Find More